Summit continues to make very strong progress with its utrophin modulation and C. difficile infection programmes. We are extremely encouraged to note that ezutromid, the group’s lead utrophin modulator for DMD, met its primary objective in its Phase Ib modified diet clinical trial in August and has now received approval to commence a Phase II open label trial in the UK and US. The first biopsy data is expected in January 2017. Ridinilazole also met its primary objective in a Phase II trial durin ....
